Abbott Laboratories (ABT) Financials

$132.80 +0.78 (+0.59%)

Closing price 03:59 PM Eastern

Extended Trading

$132.20 -0.60 (-0.45%)

As of 07:56 PM Eastern

Annual Income Statements for Abbott Laboratories

This table shows Abbott Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	13,402	5,723	6,933	7,071	4,495	3,687	2,368	477	1,400	4,423
Consolidated Net Income / (Loss)	13,402	5,723	6,933	7,071	4,495	3,687	2,368	477	1,400	4,423
Net Income / (Loss) Continuing Operations	13,402	5,723	6,933	7,071	4,471	3,687	2,334	353	1,063	2,606
Total Pre-Tax Income	7,013	6,664	8,306	8,211	4,968	4,077	2,873	2,231	1,413	3,183
Total Operating Income	6,825	6,478	8,362	8,425	5,357	4,532	3,650	1,564	3,026	2,867
Total Gross Profit	23,244	22,134	24,511	24,538	19,605	18,673	17,872	14,981	11,759	11,658
Total Revenue	41,950	40,109	43,653	43,075	34,608	31,904	30,578	27,390	20,853	20,405
Operating Revenue	41,950	40,109	43,653	43,075	34,608	31,904	30,578	27,390	20,853	20,405
Total Cost of Revenue	18,706	17,975	19,142	18,537	15,003	13,231	12,706	12,409	9,094	8,747
Operating Cost of Revenue	18,706	17,975	19,142	18,537	15,003	13,231	12,706	12,409	9,094	8,747
Total Operating Expenses	16,419	15,656	16,149	16,113	14,248	14,141	14,222	13,417	8,733	8,791
Selling, General & Admin Expense	11,697	10,949	11,248	11,324	9,696	11,701	9,744	9,182	6,736	6,785
Research & Development Expense	2,844	2,741	2,888	2,742	2,420	2,440	2,300	2,260	1,447	1,405
Amortization Expense	1,878	1,966	2,013	2,047	2,132	-	2,178	1,975	550	601
Total Other Income / (Expense), net	188	186	-56	-214	-389	-455	-777	667	-1,613	316
Interest Expense	559	637	558	533	546	733	993	904	431	163
Interest & Investment Income	344	385	183	43	46	94	105	124	99	105
Other Income / (Expense), net	403	438	319	276	111	184	111	1,447	-1,281	374
Income Tax Expense	-6,389	941	1,373	1,140	497	390	539	1,878	350	577
Basic Earnings per Share	$7.67	$3.28	$3.94	$3.97	$2.52	$2.07	$1.34	$0.27	$0.94	$2.94
Weighted Average Basic Shares Outstanding	1.74B	1.74B	1.75B	1.78B	1.77B	1.77B	1.76B	1.74B	1.48B	1.50B
Diluted Earnings per Share	$7.64	$3.26	$3.91	$3.94	$2.50	$2.06	$1.33	$0.27	$0.94	$2.92
Weighted Average Diluted Shares Outstanding	1.75B	1.75B	1.76B	1.79B	1.79B	1.78B	1.77B	1.75B	1.48B	1.51B
Weighted Average Basic & Diluted Shares Outstanding	1.73B	1.74B	1.74B	1.76B	1.77B	1.76B	1.77B	1.75B	1.73B	1.50B
Cash Dividends to Common per Share	$2.24	$2.08	$1.92	-	-	-	-	-	-	-

This table shows Abbott Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	1,325	9,229	1,646	1,302	1,225	1,594	1,436	1,375	1,318	1,033	1,435
Consolidated Net Income / (Loss)	1,325	9,229	1,646	1,302	1,225	1,594	1,436	1,375	1,318	1,033	1,435
Net Income / (Loss) Continuing Operations	1,325	9,229	1,646	1,302	1,225	1,594	1,436	1,375	1,318	1,033	1,435
Total Pre-Tax Income	1,778	2,030	1,940	1,607	1,436	1,795	1,671	1,636	1,562	1,320	1,758
Total Operating Income	1,693	1,911	1,859	1,669	1,386	1,780	1,647	1,542	1,509	1,304	1,770
Total Gross Profit	5,890	6,032	5,937	5,774	5,501	5,685	5,538	5,495	5,416	5,498	5,781
Total Revenue	10,358	10,974	10,635	10,377	9,964	10,241	10,143	9,978	9,747	10,091	10,410
Operating Revenue	10,358	10,974	10,635	10,377	9,964	10,241	10,143	9,978	9,747	10,091	10,410
Total Cost of Revenue	4,468	4,942	4,698	4,603	4,463	4,556	4,605	4,483	4,331	4,593	4,629
Operating Cost of Revenue	4,468	4,942	4,698	4,603	4,463	4,556	4,605	4,483	4,331	4,593	4,629
Total Operating Expenses	4,197	4,121	4,078	4,105	4,115	3,905	3,891	3,953	3,907	4,194	4,011
Selling, General & Admin Expense	3,061	2,907	2,895	2,936	2,959	2,724	2,723	2,740	2,762	2,973	2,731
Research & Development Expense	716	749	713	698	684	700	672	715	654	725	782
Amortization Expense	420	465	470	471	472	481	496	498	491	496	498
Total Other Income / (Expense), net	85	119	81	-62	50	15	24	94	53	16	-12
Interest Expense	131	136	142	140	141	159	166	159	153	154	141
Interest & Investment Income	82	91	91	82	80	89	97	98	101	88	55
Other Income / (Expense), net	134	164	132	-4.00	111	85	93	155	105	82	74
Income Tax Expense	453	-7,199	294	305	211	201	235	261	244	287	323
Basic Earnings per Share	$0.76	$5.29	$0.94	$0.74	$0.70	$0.92	$0.82	$0.79	$0.75	$0.59	$0.82
Weighted Average Basic Shares Outstanding	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.75B	1.75B
Diluted Earnings per Share	$0.76	$5.26	$0.94	$0.74	$0.70	$0.91	$0.82	$0.78	$0.75	$0.59	$0.81
Weighted Average Diluted Shares Outstanding	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.76B	1.76B
Weighted Average Basic & Diluted Shares Outstanding	1.74B	1.73B	1.73B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B
Cash Dividends to Common per Share	$0.59	-	$0.55	-	-	-	$0.51	-	-	-	-

This table details how cash moves in and out of Abbott Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	720	-2,986	83	2,961	2,978	16	-5,447	-9,329	13,619	938
Net Cash From Operating Activities	8,558	7,261	9,581	10,533	7,901	6,136	6,300	5,570	3,203	2,966
Net Cash From Continuing Operating Activities	8,558	7,261	9,581	10,533	7,901	6,136	6,300	5,570	3,203	2,966
Net Income / (Loss) Continuing Operations	13,402	5,723	6,933	7,071	4,495	3,687	2,368	477	1,400	4,423
Consolidated Net Income / (Loss)	13,402	5,723	6,933	7,071	4,495	3,687	2,368	477	1,400	4,423
Depreciation Expense	1,340	1,277	1,254	1,491	1,195	1,078	1,100	1,046	803	871
Amortization Expense	1,878	1,966	2,013	2,047	2,132	1,936	2,210	2,887	715	601
Non-Cash Adjustments To Reconcile Net Income	1,155	770	900	695	971	766	770	-755	1,798	-2,773
Changes in Operating Assets and Liabilities, net	-9,217	-2,475	-1,519	-771	-892	-1,331	-148	1,915	-1,513	-156
Net Cash From Investing Activities	-2,338	-3,133	-1,740	-2,008	-2,215	-1,815	-1,356	-9,618	-248	406
Net Cash From Continuing Investing Activities	-2,338	-3,133	-1,740	-2,008	-2,215	-1,815	-1,356	-9,618	-248	406
Purchase of Property, Plant & Equipment	-2,207	-2,202	-1,777	-1,885	-2,177	-1,638	-1,394	-1,135	-1,121	-1,110
Acquisitions	0.00	-877	0.00	-187	-42	-170	-54	-17,183	-80	-235
Purchase of Investments	-169	-159	-185	-173	-83	-103	-131	-210	-2,823	-4,933
Divestitures	1.00	40	48	134	58	48	48	6,042	25	230
Sale and/or Maturity of Investments	28	43	152	77	10	21	73	2,833	3,709	6,402
Other Investing Activities, net	9.00	22	22	26	19	27	102	35	42	52
Net Cash From Financing Activities	-5,404	-7,091	-7,636	-5,494	-2,779	-4,289	-10,391	-5,281	11,147	-2,236
Net Cash From Continuing Financing Activities	-5,404	-7,091	-7,636	-5,494	-2,779	-4,289	-10,391	-5,281	11,147	-2,236
Repayment of Debt	-760	-2,477	-706	-252	-1,342	-3,441	-12,459	-9,684	-1,949	-1,338
Repurchase of Common Equity	-1,295	-1,227	-3,795	-2,299	-403	-718	-238	-117	-522	-2,237
Payment of Dividends	-3,836	-3,556	-3,309	-3,202	-2,560	-2,270	-1,974	-1,849	-1,539	-1,443
Issuance of Debt	223	2.00	7.00	4.00	1,281	1,842	4,009	6,742	14,934	2,485
Other Financing Activities, net	264	167	167	255	245	298	271	337	223	297
Effect of Exchange Rate Changes	-96	-23	-122	-70	71	-16	-	-	-483	-198
Cash Interest Paid	604	662	563	544	549	677	845	917	181	166
Cash Income Taxes Paid	1,723	1,475	1,864	1,941	970	930	740	570	620	631

This table details how cash moves in and out of Abbott Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-1,084	58	571	703	-612	187	-1,126	-1,326	-721	288	657
Net Cash From Operating Activities	1,417	2,868	2,705	1,960	1,025	3,038	1,877	1,203	1,143	2,326	2,780
Net Cash From Continuing Operating Activities	1,417	2,868	2,705	1,960	1,025	3,038	1,877	1,203	1,143	2,326	2,780
Net Income / (Loss) Continuing Operations	1,325	9,229	1,646	1,302	1,225	1,594	1,436	1,375	1,318	1,033	1,435
Consolidated Net Income / (Loss)	1,325	9,229	1,646	1,302	1,225	1,594	1,436	1,375	1,318	1,033	1,435
Depreciation Expense	336	342	331	334	333	332	328	302	315	311	317
Amortization Expense	420	465	470	471	472	481	496	498	491	496	498
Non-Cash Adjustments To Reconcile Net Income	289	593	117	141	304	240	117	132	281	330	123
Changes in Operating Assets and Liabilities, net	-953	-7,761	141	-288	-1,309	391	-500	-1,104	-1,262	156	407
Net Cash From Investing Activities	-470	-866	-594	-453	-425	-824	-634	-1,213	-462	-632	-484
Net Cash From Continuing Investing Activities	-470	-866	-594	-453	-425	-824	-634	-1,213	-462	-632	-484
Purchase of Property, Plant & Equipment	-484	-720	-556	-533	-398	-755	-560	-507	-380	-610	-467
Sale and/or Maturity of Investments	8.00	-	-	-	-	-	-	-	-	-	-
Other Investing Activities, net	6.00	4.00	2.00	2.00	1.00	2.00	15	1.00	4.00	8.00	4.00
Net Cash From Financing Activities	-2,055	-1,861	-1,576	-791	-1,176	-2,052	-2,340	-1,289	-1,410	-1,457	-1,543
Net Cash From Continuing Financing Activities	-2,055	-1,861	-1,576	-791	-1,176	-2,052	-2,340	-1,289	-1,410	-1,457	-1,543
Repayment of Debt	-1,037	-614	42	-61	-127	-940	-1,506	11	-42	10	23
Repurchase of Common Equity	-280	-315	-751	-3.00	-226	-259	-2.00	-426	-540	-685	-798
Payment of Dividends	-1,026	-958	-960	-961	-957	-888	-888	-890	-890	-823	-826
Issuance of Debt	1.00	1.00	1.00	-	-	1.00	-	-	-	-	1.00
Other Financing Activities, net	287	25	92	13	134	34	56	15	62	41	57
Effect of Exchange Rate Changes	24	-83	36	-13	-36	25	-	-	8.00	51	-96

This table presents Abbott Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	81,414	73,214	74,438	75,196	72,548	67,887	67,173	76,250	52,666	41,247
Total Current Assets	23,656	22,670	25,224	24,239	20,441	15,667	14,632	20,147	26,776	14,155
Cash & Equivalents	7,616	6,896	9,882	9,799	6,838	3,860	3,844	9,407	18,620	5,001
Short-Term Investments	351	383	288	450	310	280	242	203	155	1,124
Accounts Receivable	6,925	6,565	6,218	6,487	6,414	5,425	5,182	5,249	3,248	3,418
Inventories, net	6,194	6,570	6,173	5,157	5,012	4,316	3,796	3,601	2,434	2,599
Prepaid Expenses	2,570	2,256	2,663	2,346	1,867	1,786	1,568	1,667	-	-
Plant, Property, & Equipment, net	10,658	10,154	9,162	8,959	9,029	8,038	7,563	7,607	5,705	5,730
Plant, Property & Equipment, gross	22,740	21,933	20,212	19,364	18,793	16,799	15,706	15,265	12,366	12,383
Accumulated Depreciation	12,082	11,779	11,050	10,405	9,764	8,761	8,143	7,658	6,661	6,653
Total Noncurrent Assets	47,100	40,390	40,052	41,998	43,078	44,182	44,978	48,496	20,185	21,362
Long-Term Investments	886	799	766	816	821	883	897	883	2,947	4,041
Goodwill	23,108	23,679	22,799	23,231	23,744	23,195	23,254	24,020	7,683	9,638
Intangible Assets	6,647	8,815	10,454	12,739	14,784	17,025	18,942	21,473	4,539	5,562
Noncurrent Deferred & Refundable Income Taxes	16,459	7,097	6,033	5,212	3,729	3,079	1,885	1,944	2,263	2,119
Total Liabilities & Shareholders' Equity	81,414	73,214	74,438	75,196	72,548	67,887	67,173	76,250	52,666	41,247
Total Liabilities	33,513	34,387	37,533	39,172	39,545	36,586	36,451	45,152	31,949	19,921
Total Current Liabilities	14,157	13,841	15,489	13,105	11,907	10,863	9,012	8,912	6,660	9,186
Short-Term Debt	1,500	1,080	2,251	754	220	1,478	207	714	1,325	3,130
Accounts Payable	4,195	4,295	4,607	4,408	3,946	3,252	2,975	2,402	1,178	1,081
Accrued Expenses	5,143	5,422	5,845	5,181	5,165	4,035	3,780	3,811	2,581	3,043
Dividends Payable	1,024	955	887	831	798	635	563	489	391	383
Current Deferred & Payable Income Tax Liabilities	594	492	343	306	362	226	305	309	188	430
Current Employee Benefit Liabilities	1,701	1,597	1,556	1,625	1,416	1,237	1,182	1,187	752	746
Total Noncurrent Liabilities	19,356	20,546	22,044	26,067	27,638	25,723	27,439	36,240	25,289	10,735
Long-Term Debt	12,625	13,599	14,522	17,296	18,527	16,661	19,359	27,210	20,681	5,871
Other Noncurrent Operating Liabilities	6,731	6,947	7,522	8,771	9,111	9,062	-	-	4,549	4,864
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	47,901	38,827	36,905	36,024	33,003	31,301	30,722	31,098	20,717	21,326
Total Preferred & Common Equity	47,664	38,603	36,686	35,802	32,784	31,088	30,524	30,897	20,538	21,211
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	47,664	38,603	36,686	35,802	32,784	31,088	30,524	30,897	20,538	21,211
Common Stock	25,153	24,869	24,709	24,470	24,145	23,853	23,512	23,206	13,027	12,734
Retained Earnings	47,261	37,554	35,257	31,528	27,627	25,847	24,560	23,978	25,565	25,757
Treasury Stock	-16,844	-	-	-	-10,042	-10,147	-	-10,225	-10,791	-10,622
Accumulated Other Comprehensive Income / (Loss)	-7,906	-7,839	-8,051	-8,374	-8,946	-8,465	-7,586	-6,062	-7,263	-6,658
Noncontrolling Interest	237	224	219	222	219	213	198	201	179	115

This table presents Abbott Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	81,448	81,414	74,356	73,017	72,467	73,214	72,090	73,354	73,794	74,438	72,801
Total Current Assets	23,153	23,656	23,802	23,119	22,376	22,670	22,664	23,505	24,377	25,224	24,845
Cash & Equivalents	6,532	7,616	7,558	6,987	6,284	6,896	6,709	7,835	9,161	9,882	9,594
Short-Term Investments	312	351	230	232	367	383	338	320	371	288	313
Accounts Receivable	7,327	6,925	7,051	6,854	6,605	6,565	6,499	6,172	6,020	6,218	6,408
Inventories, net	6,639	6,194	6,813	6,814	6,827	6,570	6,650	6,871	6,673	6,173	5,734
Prepaid Expenses	2,343	2,570	2,150	2,232	2,293	2,256	2,468	2,307	2,152	2,663	2,796
Plant, Property, & Equipment, net	10,932	10,658	10,621	10,233	10,107	10,154	9,552	9,449	9,282	9,162	8,689
Plant, Property & Equipment, gross	23,418	22,740	22,857	22,061	22,055	21,933	21,111	20,926	20,605	20,212	19,306
Accumulated Depreciation	12,486	12,082	12,236	11,828	11,948	11,779	11,559	11,477	11,323	11,050	10,617
Total Noncurrent Assets	47,363	47,100	39,933	39,665	39,984	40,390	39,874	40,400	40,135	40,052	39,267
Long-Term Investments	907	886	912	877	818	799	788	799	776	766	764
Goodwill	23,359	23,108	23,658	23,308	23,383	23,679	23,277	23,258	22,927	22,799	22,284
Intangible Assets	6,261	6,647	7,352	7,827	8,296	8,815	9,282	9,834	10,006	10,454	10,850
Noncurrent Deferred & Refundable Income Taxes	16,836	16,459	8,011	7,653	7,487	7,097	6,527	6,509	6,426	6,033	5,369
Total Liabilities & Shareholders' Equity	81,448	81,414	74,356	73,017	72,467	73,214	72,090	73,354	73,794	74,438	72,801
Total Liabilities	32,384	33,513	34,328	33,457	33,424	34,387	34,396	35,950	36,562	37,533	36,917
Total Current Liabilities	13,004	14,157	14,902	13,760	14,021	13,841	13,042	14,350	14,530	15,489	13,365
Short-Term Debt	506	1,500	2,154	1,615	2,010	1,080	1,051	2,284	2,285	2,251	1,117
Accounts Payable	4,214	4,195	4,034	4,125	4,178	4,295	3,961	4,211	4,167	4,607	4,133
Accrued Expenses	5,600	5,143	5,427	5,071	5,220	5,422	5,347	5,334	5,758	5,845	5,475
Dividends Payable	1,032	1,024	956	959	959	955	886	886	888	887	820
Current Deferred & Payable Income Tax Liabilities	485	594	713	601	562	492	318	273	334	343	394
Current Employee Benefit Liabilities	1,167	1,701	1,618	1,389	1,092	1,597	1,479	1,362	1,098	1,556	1,426
Total Noncurrent Liabilities	19,380	19,356	19,426	19,697	19,403	20,546	21,354	21,600	22,032	22,044	23,552
Long-Term Debt	12,736	12,625	12,825	13,139	12,576	13,599	14,477	14,562	14,615	14,522	15,297
Noncurrent Deferred & Payable Income Tax Liabilities	6,644	-	6,601	6,558	6,827	-	6,877	7,038	7,417	-	8,255
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	49,064	47,901	40,028	39,560	39,043	38,827	37,694	37,404	37,232	36,905	35,884
Total Preferred & Common Equity	48,811	47,664	39,796	39,318	38,810	38,603	37,481	37,174	37,010	36,686	35,675
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	48,811	47,664	39,796	39,318	38,810	38,603	37,481	37,174	37,010	36,686	35,675
Common Stock	25,125	25,153	25,020	24,858	24,726	24,869	24,727	24,612	24,488	24,709	24,560
Retained Earnings	47,715	47,261	39,056	38,354	38,011	37,554	36,920	36,355	35,868	35,257	35,115
Treasury Stock	-16,612	-16,844	-16,476	-15,759	-	-	-15,686	-15,722	-15,307	-	-
Accumulated Other Comprehensive Income / (Loss)	-7,417	-7,906	-7,804	-8,135	-8,166	-7,839	-8,480	-8,071	-8,039	-8,051	-9,445
Noncontrolling Interest	253	237	232	242	233	224	213	230	222	219	209

This table displays calculated financial ratios and metrics derived from Abbott Laboratories' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.59%	-8.12%	1.34%	24.47%	8.48%	4.34%	11.64%	31.35%	2.20%	0.78%
EBITDA Growth	2.83%	-14.97%	-2.38%	39.16%	13.78%	9.32%	1.83%	112.81%	-30.77%	13.38%
EBIT Growth	4.51%	-20.33%	-0.23%	59.13%	15.95%	25.39%	24.91%	72.55%	-46.16%	24.22%
NOPAT Growth	134.44%	-20.29%	-3.80%	50.49%	17.63%	38.22%	1,098.25%	-89.13%	-3.02%	32.14%
Net Income Growth	134.18%	-17.45%	-1.95%	57.31%	21.91%	55.70%	396.44%	-65.93%	-68.35%	93.65%
EPS Growth	134.36%	-16.62%	-0.76%	57.60%	21.36%	54.89%	392.59%	-71.28%	-67.81%	95.97%
Operating Cash Flow Growth	17.86%	-24.21%	-9.04%	33.31%	28.76%	-2.60%	13.11%	73.90%	7.99%	-19.29%
Free Cash Flow Firm Growth	86.12%	-60.93%	-10.05%	51.00%	7.72%	-16.97%	119.64%	-747.37%	0.33%	84.66%
Invested Capital Growth	16.85%	6.31%	-0.48%	-1.66%	-1.05%	-1.78%	-6.05%	164.91%	-11.44%	-9.93%
Revenue Q/Q Growth	1.78%	0.38%	-3.06%	1.81%	7.41%	1.75%	0.58%	8.98%	0.70%	-0.70%
EBITDA Q/Q Growth	1.99%	5.01%	-8.69%	-0.42%	15.54%	3.34%	3.63%	3.15%	9.50%	-0.59%
EBIT Q/Q Growth	2.99%	7.44%	-10.89%	-0.78%	24.41%	5.76%	11.90%	-6.78%	10.44%	0.03%
NOPAT Q/Q Growth	129.00%	11.13%	-12.68%	-2.24%	26.98%	9.32%	190.04%	-81.43%	2.76%	1.16%
Net Income Q/Q Growth	132.39%	10.87%	-12.12%	-2.39%	32.91%	12.00%	167.27%	-77.32%	2.26%	-3.03%
EPS Q/Q Growth	132.22%	10.88%	-11.74%	-2.23%	32.28%	11.96%	171.43%	-78.91%	3.30%	-4.26%
Operating Cash Flow Q/Q Growth	-1.95%	10.87%	-7.18%	-6.49%	21.20%	11.87%	2.02%	9.22%	11.95%	-12.14%
Free Cash Flow Firm Q/Q Growth	11.12%	138.07%	-18.97%	-14.56%	6.70%	32.18%	551.28%	-30.39%	126.77%	-82.50%
Invested Capital Q/Q Growth	14.67%	0.24%	2.78%	1.18%	-1.51%	-2.96%	-1.14%	10.80%	-6.03%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	55.41%	55.18%	56.15%	56.97%	56.65%	58.53%	58.45%	54.70%	56.39%	57.13%
EBITDA Margin	24.90%	25.33%	27.37%	28.41%	25.41%	24.23%	23.12%	25.35%	15.65%	23.10%
Operating Margin	16.27%	16.15%	19.16%	19.56%	15.48%	14.21%	11.94%	5.71%	14.51%	14.05%
EBIT Margin	17.23%	17.24%	19.89%	20.20%	15.80%	14.78%	12.30%	10.99%	8.37%	15.88%
Profit (Net Income) Margin	31.95%	14.27%	15.88%	16.42%	12.99%	11.56%	7.74%	1.74%	6.71%	21.68%
Tax Burden Percent	191.10%	85.88%	83.47%	86.12%	90.48%	90.43%	82.42%	21.38%	99.08%	138.96%
Interest Burden Percent	97.03%	96.36%	95.68%	94.37%	90.86%	86.45%	76.39%	74.10%	80.97%	98.21%
Effective Tax Rate	-91.10%	14.12%	16.53%	13.88%	10.00%	9.57%	18.76%	84.18%	24.77%	18.13%
Return on Invested Capital (ROIC)	25.94%	12.36%	15.96%	16.41%	10.76%	9.02%	6.26%	0.74%	11.60%	10.69%
ROIC Less NNEP Spread (ROIC-NNEP)	31.12%	14.60%	15.32%	14.51%	8.18%	6.17%	2.63%	3.71%	74.14%	448.14%
Return on Net Nonoperating Assets (RNNOA)	4.97%	2.75%	3.05%	4.08%	3.22%	2.87%	1.40%	1.11%	-4.94%	9.90%
Return on Equity (ROE)	30.91%	15.11%	19.01%	20.49%	13.98%	11.89%	7.66%	1.84%	6.66%	20.59%
Cash Return on Invested Capital (CROIC)	10.40%	6.24%	16.44%	18.08%	11.81%	10.81%	12.50%	-89.65%	23.73%	21.14%
Operating Return on Assets (OROA)	9.35%	9.37%	11.60%	11.78%	7.79%	6.98%	5.24%	4.67%	3.72%	7.86%
Return on Assets (ROA)	17.33%	7.75%	9.27%	9.57%	6.40%	5.46%	3.30%	0.74%	2.98%	10.73%
Return on Common Equity (ROCE)	30.74%	15.03%	18.90%	20.36%	13.89%	11.81%	7.61%	1.83%	6.61%	20.48%
Return on Equity Simple (ROE_SIMPLE)	28.12%	14.83%	18.90%	19.75%	13.71%	11.86%	7.76%	1.54%	6.82%	20.85%
Net Operating Profit after Tax (NOPAT)	13,043	5,563	6,980	7,255	4,821	4,098	2,965	247	2,276	2,347
NOPAT Margin	31.09%	13.87%	15.99%	16.84%	13.93%	12.85%	9.70%	0.90%	10.92%	11.50%
Net Nonoperating Expense Percent (NNEP)	-5.19%	-2.24%	0.64%	1.90%	2.58%	2.85%	3.63%	-2.97%	-62.54%	-437.45%
Return On Investment Capital (ROIC_SIMPLE)	21.03%	10.40%	13.00%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	44.59%	44.82%	43.85%	43.03%	43.35%	41.47%	41.55%	45.30%	43.61%	42.87%
SG&A Expenses to Revenue	27.88%	27.30%	25.77%	26.29%	28.02%	36.68%	31.87%	33.52%	32.30%	33.25%
R&D to Revenue	6.78%	6.83%	6.62%	6.37%	6.99%	7.65%	7.52%	8.25%	6.94%	6.89%
Operating Expenses to Revenue	39.14%	39.03%	36.99%	37.41%	41.17%	44.32%	46.51%	48.99%	41.88%	43.08%
Earnings before Interest and Taxes (EBIT)	7,228	6,916	8,681	8,701	5,468	4,716	3,761	3,011	1,745	3,241
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	10,446	10,159	11,948	12,239	8,795	7,730	7,071	6,944	3,263	4,713
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.09	4.83	4.99	6.60	5.54	4.55	3.77	2.86	2.39	2.68
Price to Tangible Book Value (P/TBV)	10.90	30.51	53.32	0.00	0.00	0.00	0.00	0.00	5.91	9.44
Price to Revenue (P/Rev)	4.65	4.65	4.19	5.49	5.24	4.43	3.76	3.23	2.36	2.78
Price to Earnings (P/E)	14.56	32.57	26.40	33.43	40.38	38.36	48.59	185.24	35.12	12.83
Dividend Yield	1.96%	1.90%	1.79%	1.35%	1.41%	1.60%	1.71%	2.09%	3.11%	2.52%
Earnings Yield	6.87%	3.07%	3.79%	2.99%	2.48%	2.61%	2.06%	0.54%	2.85%	7.79%
Enterprise Value to Invested Capital (EV/IC)	3.70	4.17	4.33	5.56	4.32	3.44	2.83	2.17	2.69	2.68
Enterprise Value to Revenue (EV/Rev)	4.78	4.82	4.33	5.65	5.56	4.85	4.25	3.87	2.38	2.73
Enterprise Value to EBITDA (EV/EBITDA)	19.21	19.02	15.83	19.90	21.89	20.02	18.36	15.26	15.21	11.82
Enterprise Value to EBIT (EV/EBIT)	27.76	27.93	21.78	27.99	35.21	32.82	34.53	35.20	28.44	17.19
Enterprise Value to NOPAT (EV/NOPAT)	15.39	34.73	27.09	33.57	39.93	37.76	43.79	428.31	21.80	23.73
Enterprise Value to Operating Cash Flow (EV/OCF)	23.45	26.61	19.74	23.13	24.36	25.22	20.61	19.03	15.49	18.78
Enterprise Value to Free Cash Flow (EV/FCFF)	38.38	68.77	26.30	30.47	36.36	31.49	21.94	0.00	10.66	12.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.29	0.38	0.45	0.50	0.57	0.58	0.64	0.90	1.06	0.42
Long-Term Debt to Equity	0.26	0.35	0.39	0.48	0.56	0.53	0.63	0.88	1.00	0.28
Financial Leverage	0.16	0.19	0.20	0.28	0.39	0.47	0.53	0.30	-0.07	0.02
Leverage Ratio	1.78	1.95	2.05	2.14	2.18	2.18	2.32	2.49	2.23	1.92
Compound Leverage Factor	1.73	1.88	1.96	2.02	1.98	1.88	1.77	1.84	1.81	1.88
Debt to Total Capital	22.77%	27.43%	31.25%	33.38%	36.23%	36.69%	38.91%	47.31%	51.51%	29.68%
Short-Term Debt to Total Capital	2.42%	2.02%	4.19%	1.39%	0.43%	2.99%	0.41%	1.21%	3.10%	10.32%
Long-Term Debt to Total Capital	20.35%	25.42%	27.05%	31.99%	35.80%	33.70%	38.50%	46.10%	48.41%	19.36%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.38%	0.42%	0.41%	0.41%	0.42%	0.43%	0.39%	0.34%	0.42%	0.38%
Common Equity to Total Capital	76.85%	72.15%	68.34%	66.21%	63.35%	62.88%	60.70%	52.35%	48.07%	69.94%
Debt to EBITDA	1.35	1.44	1.40	1.47	2.13	2.35	2.77	4.02	6.74	1.91
Net Debt to EBITDA	0.50	0.65	0.49	0.57	1.23	1.70	2.06	2.51	0.09	-0.25
Long-Term Debt to EBITDA	1.21	1.34	1.22	1.41	2.11	2.16	2.74	3.92	6.34	1.25
Debt to NOPAT	1.08	2.64	2.40	2.49	3.89	4.43	6.60	112.84	9.67	3.83
Net Debt to NOPAT	0.40	1.19	0.84	0.96	2.24	3.20	4.92	70.44	0.12	-0.50
Long-Term Debt to NOPAT	0.97	2.44	2.08	2.38	3.84	4.07	6.53	109.96	9.08	2.50
Altman Z-Score	5.26	4.97	4.72	5.34	4.15	3.64	3.15	2.28	2.57	3.48
Noncontrolling Interest Sharing Ratio	0.53%	0.59%	0.60%	0.64%	0.67%	0.66%	0.65%	0.73%	0.70%	0.53%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.67	1.64	1.63	1.85	1.72	1.44	1.62	2.26	4.02	1.54
Quick Ratio	1.05	1.00	1.06	1.28	1.14	0.88	1.03	1.67	3.31	1.04
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5,229	2,809	7,191	7,994	5,294	4,914	5,919	-30,145	4,656	4,641
Operating Cash Flow to CapEx	387.77%	329.75%	539.17%	558.78%	362.93%	374.60%	451.94%	490.75%	285.73%	267.21%
Free Cash Flow to Firm to Interest Expense	9.35	4.41	12.89	15.00	9.70	6.70	5.96	-33.35	10.80	28.47
Operating Cash Flow to Interest Expense	15.31	11.40	17.17	19.76	14.47	8.37	6.34	6.16	7.43	18.20
Operating Cash Flow Less CapEx to Interest Expense	11.36	7.94	13.99	16.23	10.48	6.14	4.94	4.91	4.83	11.39
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.54	0.54	0.58	0.58	0.49	0.47	0.43	0.42	0.44	0.49
Accounts Receivable Turnover	6.22	6.28	6.87	6.68	5.85	6.02	5.86	6.45	6.26	5.83
Inventory Turnover	2.93	2.82	3.38	3.65	3.22	3.26	3.44	4.11	3.61	3.34
Fixed Asset Turnover	4.03	4.15	4.82	4.79	4.06	4.09	4.03	4.12	3.65	3.50
Accounts Payable Turnover	4.41	4.04	4.25	4.44	4.17	4.25	4.73	6.93	8.05	8.16
Days Sales Outstanding (DSO)	58.69	58.16	53.12	54.66	62.43	60.68	62.26	56.62	58.34	62.64
Days Inventory Outstanding (DIO)	124.53	129.38	108.02	100.12	113.47	111.89	106.25	88.76	101.00	109.37
Days Payable Outstanding (DPO)	82.83	90.38	85.95	82.25	87.56	85.89	77.23	52.65	45.33	44.75
Cash Conversion Cycle (CCC)	100.39	97.16	75.19	72.53	88.34	86.68	91.27	92.72	114.01	127.26
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	54,197	46,383	43,629	43,840	44,579	45,052	45,868	48,822	18,430	20,810
Invested Capital Turnover	0.83	0.89	1.00	0.97	0.77	0.70	0.65	0.81	1.06	0.93
Increase / (Decrease) in Invested Capital	7,814	2,754	-211	-739	-473	-816	-2,954	30,392	-2,380	-2,294
Enterprise Value (EV)	200,669	193,196	189,096	243,582	192,505	154,775	129,850	105,991	49,625	55,710
Market Capitalization	195,160	186,371	183,040	236,375	181,508	141,446	115,069	88,359	49,162	56,760
Book Value per Share	$27.48	$22.24	$21.04	$20.25	$18.50	$17.58	$17.38	$17.75	$13.95	$14.18
Tangible Book Value per Share	$10.33	$3.52	$1.97	($0.10)	($3.24)	($5.16)	($6.65)	($8.39)	$5.65	$4.02
Total Capital	62,026	53,506	53,678	54,074	51,750	49,440	50,288	59,022	42,723	30,327
Total Debt	14,125	14,679	16,773	18,050	18,747	18,139	19,566	27,924	22,006	9,001
Total Long-Term Debt	12,625	13,599	14,522	17,296	18,527	16,661	19,359	27,210	20,681	5,871
Net Debt	5,272	6,601	5,837	6,985	10,778	13,116	14,583	17,431	284	-1,165
Capital Expenditures (CapEx)	2,207	2,202	1,777	1,885	2,177	1,638	1,394	1,135	1,121	1,110
Debt-free, Cash-free Net Working Capital (DFCFNWC)	3,032	2,630	1,816	1,639	1,606	2,142	1,741	2,339	2,666	1,974
Debt-free Net Working Capital (DFNWC)	10,999	9,909	11,986	11,888	8,754	6,282	5,827	11,949	21,441	8,099
Net Working Capital (NWC)	9,499	8,829	9,735	11,134	8,534	4,804	5,620	11,235	20,116	4,969
Net Nonoperating Expense (NNE)	-359	-160	47	184	326	411	597	-230	876	-2,076
Net Nonoperating Obligations (NNO)	6,296	7,556	6,724	7,816	11,576	13,751	15,146	17,724	-2,287	-516
Total Depreciation and Amortization (D&A)	3,218	3,243	3,267	3,538	3,327	3,014	3,310	3,933	1,518	1,472
Debt-free, Cash-free Net Working Capital to Revenue	7.23%	6.56%	4.16%	3.81%	4.64%	6.71%	5.69%	8.54%	12.78%	9.67%
Debt-free Net Working Capital to Revenue	26.22%	24.71%	27.46%	27.60%	25.29%	19.69%	19.06%	43.63%	102.82%	39.69%
Net Working Capital to Revenue	22.64%	22.01%	22.30%	25.85%	24.66%	15.06%	18.38%	41.02%	96.47%	24.35%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$7.67	$3.28	$3.94	$3.97	$2.52	$2.07	$1.34	$0.27	$0.94	$2.94
Adjusted Weighted Average Basic Shares Outstanding	1.74B	1.74B	1.75B	1.78B	1.77B	1.77B	1.76B	1.74B	1.48B	1.50B
Adjusted Diluted Earnings per Share	$7.64	$3.26	$3.91	$3.94	$2.50	$2.06	$1.33	$0.27	$0.94	$2.92
Adjusted Weighted Average Diluted Shares Outstanding	1.75B	1.75B	1.76B	1.79B	1.79B	1.78B	1.77B	1.75B	1.48B	1.51B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$2.07	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.73B	1.74B	1.74B	1.76B	1.77B	1.76B	1.76B	1.75B	1.73B	1.47B
Normalized Net Operating Profit after Tax (NOPAT)	4,778	5,563	6,980	7,255	4,821	4,098	2,965	1,095	2,276	2,347
Normalized NOPAT Margin	11.39%	13.87%	15.99%	16.84%	13.93%	12.85%	9.70%	4.00%	10.92%	11.50%
Pre Tax Income Margin	16.72%	16.61%	19.03%	19.06%	14.36%	12.78%	9.40%	8.15%	6.78%	15.60%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	12.93	10.86	15.56	16.32	10.01	6.43	3.79	3.33	4.05	19.88
NOPAT to Interest Expense	23.33	8.73	12.51	13.61	8.83	5.59	2.99	0.27	5.28	14.40
EBIT Less CapEx to Interest Expense	8.98	7.40	12.37	12.79	6.03	4.20	2.38	2.08	1.45	13.07
NOPAT Less CapEx to Interest Expense	19.38	5.28	9.32	10.08	4.84	3.36	1.58	-0.98	2.68	7.59
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	28.62%	62.14%	47.73%	45.28%	56.95%	61.57%	83.36%	387.63%	109.93%	32.62%
Augmented Payout Ratio	38.29%	83.58%	102.47%	77.80%	65.92%	81.04%	93.41%	412.16%	147.21%	83.20%

This table displays calculated financial ratios and metrics derived from Abbott Laboratories' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.95%	7.16%	4.85%	4.00%	2.23%	1.49%	-2.56%	-11.36%	-18.06%	-12.01%	-4.74%
EBITDA Growth	12.21%	7.62%	8.89%	-1.08%	-4.88%	22.12%	-3.57%	-23.87%	-36.58%	-34.14%	-23.22%
EBIT Growth	22.04%	11.26%	14.43%	-1.89%	-7.25%	34.56%	-5.64%	-30.96%	-46.07%	-43.36%	-29.51%
NOPAT Growth	6.71%	449.64%	11.44%	4.34%	-7.14%	54.90%	-2.04%	-36.43%	-48.61%	-49.79%	-32.63%
Net Income Growth	8.16%	478.98%	14.62%	-5.31%	-7.06%	54.31%	0.07%	-31.86%	-46.14%	-48.06%	-31.67%
EPS Growth	8.57%	478.02%	14.63%	-5.13%	-6.67%	54.24%	1.23%	-31.58%	-45.26%	-46.85%	-30.77%
Operating Cash Flow Growth	38.24%	-5.60%	44.11%	62.93%	-10.32%	30.61%	-32.48%	-50.08%	-44.65%	-24.16%	2.92%
Free Cash Flow Firm Growth	-488.44%	174.49%	124.36%	158.56%	-203.50%	-195.28%	-203.65%	-145.43%	-29.76%	-55.57%	-42.99%
Invested Capital Growth	17.97%	16.85%	2.14%	2.15%	5.38%	6.31%	9.01%	4.30%	0.20%	-0.48%	-2.03%
Revenue Q/Q Growth	-5.61%	3.19%	2.49%	4.14%	-2.70%	0.97%	1.65%	2.37%	-3.41%	-3.06%	-7.52%
EBITDA Q/Q Growth	-10.37%	3.22%	13.04%	7.30%	-14.04%	4.45%	2.68%	3.18%	10.35%	-17.53%	-18.93%
EBIT Q/Q Growth	-11.95%	4.22%	19.58%	11.22%	-19.73%	7.18%	2.53%	5.14%	16.45%	-24.84%	-24.98%
NOPAT Q/Q Growth	-85.48%	450.82%	16.64%	14.37%	-25.20%	11.68%	9.21%	1.78%	24.77%	-29.37%	-29.13%
Net Income Q/Q Growth	-85.64%	460.69%	26.42%	6.29%	-23.15%	11.00%	4.44%	4.32%	27.59%	-28.01%	-28.89%
EPS Q/Q Growth	-85.55%	459.57%	27.03%	5.71%	-23.08%	10.98%	5.13%	4.00%	27.12%	-27.16%	-28.95%
Operating Cash Flow Q/Q Growth	-50.59%	6.03%	38.01%	91.22%	-66.26%	61.85%	56.03%	5.25%	-50.86%	-16.33%	15.35%
Free Cash Flow Firm Q/Q Growth	-924.53%	48.82%	64.40%	129.17%	-4.38%	51.33%	-295.18%	-151.55%	-3.91%	-47.05%	73.23%
Invested Capital Q/Q Growth	2.56%	14.67%	0.18%	0.12%	1.59%	0.24%	0.20%	3.29%	2.48%	2.78%	-4.13%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	56.86%	54.97%	55.83%	55.64%	55.21%	55.51%	54.60%	55.07%	55.57%	54.48%	55.53%
EBITDA Margin	24.94%	26.26%	26.25%	23.80%	23.10%	26.15%	25.28%	25.03%	24.83%	21.73%	25.54%
Operating Margin	16.34%	17.41%	17.48%	16.08%	13.91%	17.38%	16.24%	15.45%	15.48%	12.92%	17.00%
EBIT Margin	17.64%	18.91%	18.72%	16.05%	15.02%	18.21%	17.15%	17.01%	16.56%	13.74%	17.71%
Profit (Net Income) Margin	12.79%	84.10%	15.48%	12.55%	12.29%	15.56%	14.16%	13.78%	13.52%	10.24%	13.78%
Tax Burden Percent	74.52%	454.63%	84.85%	81.02%	85.31%	88.80%	85.94%	84.05%	84.38%	78.26%	81.63%
Interest Burden Percent	97.32%	97.83%	97.44%	96.52%	95.93%	96.25%	96.03%	96.41%	96.78%	95.24%	95.34%
Effective Tax Rate	25.48%	-354.63%	15.15%	18.98%	14.69%	11.20%	14.06%	15.95%	15.62%	21.74%	18.37%
Return on Invested Capital (ROIC)	10.04%	66.04%	13.07%	11.37%	10.42%	13.76%	12.57%	11.55%	12.14%	10.09%	14.57%
ROIC Less NNEP Spread (ROIC-NNEP)	10.91%	73.85%	13.94%	10.76%	10.97%	13.94%	12.84%	12.52%	12.68%	10.27%	14.44%
Return on Net Nonoperating Assets (RNNOA)	1.81%	11.80%	2.84%	2.29%	2.24%	2.63%	2.64%	2.76%	2.87%	2.05%	3.12%
Return on Equity (ROE)	11.85%	77.83%	15.91%	13.66%	12.66%	16.38%	15.21%	14.31%	15.01%	12.14%	17.70%
Cash Return on Invested Capital (CROIC)	9.01%	10.40%	10.06%	9.72%	6.68%	6.24%	2.66%	6.92%	12.73%	16.44%	20.69%
Operating Return on Assets (OROA)	9.71%	10.26%	10.54%	8.93%	8.28%	9.89%	9.46%	9.27%	9.30%	8.01%	10.88%
Return on Assets (ROA)	7.04%	45.63%	8.71%	6.98%	6.78%	8.46%	7.81%	7.51%	7.59%	5.97%	8.47%
Return on Common Equity (ROCE)	11.79%	77.42%	15.82%	13.58%	12.58%	16.29%	15.13%	14.22%	14.91%	12.07%	17.59%
Return on Equity Simple (ROE_SIMPLE)	27.66%	0.00%	14.49%	14.13%	14.51%	0.00%	13.77%	13.88%	15.68%	0.00%	22.11%
Net Operating Profit after Tax (NOPAT)	1,262	8,688	1,577	1,352	1,182	1,581	1,415	1,296	1,273	1,020	1,445
NOPAT Margin	12.18%	79.17%	14.83%	13.03%	11.87%	15.43%	13.95%	12.99%	13.06%	10.11%	13.88%
Net Nonoperating Expense Percent (NNEP)	-0.87%	-7.81%	-0.87%	0.61%	-0.55%	-0.19%	-0.27%	-0.97%	-0.54%	-0.17%	0.13%
Return On Investment Capital (ROIC_SIMPLE)	2.02%	14.01%	-	-	-	2.95%	-	-	-	1.90%	-
Cost of Revenue to Revenue	43.14%	45.03%	44.17%	44.36%	44.79%	44.49%	45.40%	44.93%	44.43%	45.52%	44.47%
SG&A Expenses to Revenue	29.55%	26.49%	27.22%	28.29%	29.70%	26.60%	26.85%	27.46%	28.34%	29.46%	26.23%
R&D to Revenue	6.91%	6.83%	6.70%	6.73%	6.86%	6.84%	6.63%	7.17%	6.71%	7.18%	7.51%
Operating Expenses to Revenue	40.52%	37.55%	38.35%	39.56%	41.30%	38.13%	38.36%	39.62%	40.08%	41.56%	38.53%
Earnings before Interest and Taxes (EBIT)	1,827	2,075	1,991	1,665	1,497	1,865	1,740	1,697	1,614	1,386	1,844
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	2,583	2,882	2,792	2,470	2,302	2,678	2,564	2,497	2,420	2,193	2,659
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.69	4.09	4.96	4.57	5.03	4.83	4.37	4.97	4.61	4.99	4.57
Price to Tangible Book Value (P/TBV)	11.93	10.90	22.47	21.97	27.39	30.51	33.29	45.28	41.87	53.32	64.10
Price to Revenue (P/Rev)	5.41	4.65	4.79	4.42	4.84	4.65	4.10	4.59	4.11	4.19	3.62
Price to Earnings (P/E)	16.96	14.56	34.24	32.36	34.69	32.57	31.75	35.81	29.41	26.40	20.65
Dividend Yield	1.70%	1.96%	1.90%	2.05%	1.85%	1.90%	2.12%	1.84%	1.95%	1.79%	2.00%
Earnings Yield	5.90%	6.87%	2.92%	3.09%	2.88%	3.07%	3.15%	2.79%	3.40%	3.79%	4.84%
Enterprise Value to Invested Capital (EV/IC)	4.22	3.70	4.32	3.96	4.30	4.17	3.71	4.18	3.97	4.33	3.98
Enterprise Value to Revenue (EV/Rev)	5.54	4.78	4.95	4.58	5.03	4.82	4.30	4.80	4.28	4.33	3.75
Enterprise Value to EBITDA (EV/EBITDA)	21.88	19.21	19.91	18.65	20.18	19.02	17.76	19.75	16.83	15.83	12.90
Enterprise Value to EBIT (EV/EBIT)	31.06	27.76	29.06	27.59	29.81	27.93	26.69	29.50	24.31	21.78	17.33
Enterprise Value to NOPAT (EV/NOPAT)	17.93	15.39	35.81	33.74	37.03	34.73	34.31	38.31	30.73	27.09	21.12
Enterprise Value to Operating Cash Flow (EV/OCF)	26.23	23.45	23.37	23.63	28.37	26.61	26.23	25.89	20.50	19.74	16.36
Enterprise Value to Free Cash Flow (EV/FCFF)	50.76	38.38	43.34	41.14	66.11	68.77	145.57	61.63	31.22	26.30	19.02
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.27	0.29	0.37	0.37	0.37	0.38	0.41	0.45	0.45	0.45	0.46
Long-Term Debt to Equity	0.26	0.26	0.32	0.33	0.32	0.35	0.38	0.39	0.39	0.39	0.43
Financial Leverage	0.17	0.16	0.20	0.21	0.20	0.19	0.21	0.22	0.23	0.20	0.22
Leverage Ratio	1.75	1.78	1.88	1.90	1.92	1.95	1.97	1.99	2.03	2.05	2.08
Compound Leverage Factor	1.70	1.74	1.84	1.84	1.84	1.88	1.89	1.92	1.96	1.95	1.98
Debt to Total Capital	21.25%	22.77%	27.23%	27.16%	27.20%	27.43%	29.18%	31.05%	31.22%	31.25%	31.39%
Short-Term Debt to Total Capital	0.81%	2.42%	3.92%	2.97%	3.75%	2.02%	1.97%	4.21%	4.22%	4.19%	2.14%
Long-Term Debt to Total Capital	20.44%	20.35%	23.32%	24.19%	23.45%	25.42%	27.20%	26.84%	27.00%	27.05%	29.25%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.41%	0.38%	0.42%	0.45%	0.43%	0.42%	0.40%	0.42%	0.41%	0.41%	0.40%
Common Equity to Total Capital	78.34%	76.85%	72.35%	72.39%	72.37%	72.15%	70.42%	68.52%	68.37%	68.34%	68.21%
Debt to EBITDA	1.23	1.35	1.46	1.47	1.45	1.44	1.61	1.72	1.60	1.40	1.25
Net Debt to EBITDA	0.51	0.50	0.61	0.66	0.71	0.65	0.80	0.81	0.62	0.49	0.44
Long-Term Debt to EBITDA	1.19	1.21	1.25	1.31	1.25	1.34	1.50	1.49	1.39	1.22	1.17
Debt to NOPAT	1.01	1.08	2.63	2.67	2.67	2.64	3.10	3.34	2.93	2.40	2.05
Net Debt to NOPAT	0.42	0.40	1.10	1.20	1.30	1.19	1.54	1.57	1.14	0.84	0.72
Long-Term Debt to NOPAT	0.97	0.97	2.25	2.37	2.30	2.44	2.89	2.89	2.53	2.08	1.91
Altman Z-Score	5.81	5.05	4.97	4.75	5.00	4.75	4.37	4.55	4.28	4.39	4.21
Noncontrolling Interest Sharing Ratio	0.55%	0.53%	0.57%	0.61%	0.60%	0.59%	0.57%	0.62%	0.62%	0.60%	0.60%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.78	1.67	1.60	1.68	1.60	1.64	1.74	1.64	1.68	1.63	1.86
Quick Ratio	1.09	1.05	1.00	1.02	0.95	1.00	1.04	1.00	1.07	1.06	1.22
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-7,206	874	587	357	-1,225	-1,173	-2,411	-610	1,183	1,231	2,326
Operating Cash Flow to CapEx	292.77%	398.33%	486.51%	367.73%	257.54%	402.38%	335.18%	237.28%	300.79%	381.31%	595.29%
Free Cash Flow to Firm to Interest Expense	-55.01	6.43	4.14	2.55	-8.69	-7.38	-14.52	-3.84	7.73	8.00	16.50
Operating Cash Flow to Interest Expense	10.82	21.09	19.05	14.00	7.27	19.11	11.31	7.57	7.47	15.10	19.72
Operating Cash Flow Less CapEx to Interest Expense	7.12	15.79	15.13	10.19	4.45	14.36	7.93	4.38	4.99	11.14	16.40
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.55	0.54	0.56	0.56	0.55	0.54	0.55	0.55	0.56	0.58	0.61
Accounts Receivable Turnover	6.08	6.22	6.08	6.25	6.39	6.28	6.19	6.02	6.29	6.87	7.03
Inventory Turnover	2.78	2.93	2.72	2.66	2.68	2.82	2.91	2.82	2.99	3.38	3.51
Fixed Asset Turnover	4.03	4.03	4.09	4.14	4.16	4.15	4.38	4.40	4.56	4.82	5.14
Accounts Payable Turnover	4.46	4.41	4.58	4.37	4.34	4.04	4.45	4.14	4.14	4.25	4.74
Days Sales Outstanding (DSO)	60.05	58.69	60.00	58.37	57.14	58.16	58.95	60.66	58.04	53.12	51.93
Days Inventory Outstanding (DIO)	131.34	124.53	134.12	137.02	136.07	129.38	125.48	129.22	122.06	108.02	103.89
Days Payable Outstanding (DPO)	81.85	82.83	79.64	83.47	84.11	90.38	82.01	88.07	88.10	85.95	77.01
Cash Conversion Cycle (CCC)	109.54	100.39	114.47	111.93	109.09	97.16	102.42	101.80	92.00	75.19	78.81
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	55,587	54,197	47,263	47,177	47,119	46,383	46,273	46,182	44,712	43,629	42,447
Invested Capital Turnover	0.82	0.83	0.88	0.87	0.88	0.89	0.90	0.89	0.93	1.00	1.05
Increase / (Decrease) in Invested Capital	8,468	7,814	990	995	2,407	2,754	3,826	1,906	90	-211	-881
Enterprise Value (EV)	234,741	200,669	203,946	186,711	202,660	193,196	171,780	192,954	177,538	189,096	168,825
Market Capitalization	228,997	195,160	197,435	179,811	195,310	186,371	163,874	184,832	170,724	183,040	162,873
Book Value per Share	$28.14	$27.48	$22.87	$22.60	$22.30	$22.24	$21.60	$21.38	$21.30	$21.04	$20.37
Tangible Book Value per Share	$11.07	$10.33	$5.05	$4.70	$4.10	$3.52	$2.84	$2.35	$2.35	$1.97	$1.45
Total Capital	62,306	62,026	55,007	54,314	53,629	53,506	53,222	54,250	54,132	53,678	52,298
Total Debt	13,242	14,125	14,979	14,754	14,586	14,679	15,528	16,846	16,900	16,773	16,414
Total Long-Term Debt	12,736	12,625	12,825	13,139	12,576	13,599	14,477	14,562	14,615	14,522	15,297
Net Debt	5,491	5,272	6,279	6,658	7,117	6,601	7,693	7,892	6,592	5,837	5,743
Capital Expenditures (CapEx)	484	720	556	533	398	755	560	507	380	610	467
Debt-free, Cash-free Net Working Capital (DFCFNWC)	3,811	3,032	3,266	3,755	3,714	2,630	3,626	3,284	2,600	1,816	2,690
Debt-free Net Working Capital (DFNWC)	10,655	10,999	11,054	10,974	10,365	9,909	10,673	11,439	12,132	11,986	12,597
Net Working Capital (NWC)	10,149	9,499	8,900	9,359	8,355	8,829	9,622	9,155	9,847	9,735	11,480
Net Nonoperating Expense (NNE)	-63	-541	-69	50	-43	-13	-21	-79	-45	-13	9.80
Net Nonoperating Obligations (NNO)	6,523	6,296	7,235	7,617	8,076	7,556	8,579	8,778	7,480	6,724	6,563
Total Depreciation and Amortization (D&A)	756	807	801	805	805	813	824	800	806	807	815
Debt-free, Cash-free Net Working Capital to Revenue	9.00%	7.23%	7.92%	9.22%	9.21%	6.56%	9.07%	8.16%	6.26%	4.16%	5.97%
Debt-free Net Working Capital to Revenue	25.16%	26.22%	26.82%	26.95%	25.70%	24.71%	26.71%	28.44%	29.23%	27.46%	27.97%
Net Working Capital to Revenue	23.97%	22.64%	21.59%	22.98%	20.72%	22.01%	24.08%	22.76%	23.72%	22.30%	25.49%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.76	$5.29	$0.94	$0.74	$0.70	$0.92	$0.82	$0.79	$0.75	$0.59	$0.82
Adjusted Weighted Average Basic Shares Outstanding	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.75B	1.75B
Adjusted Diluted Earnings per Share	$0.76	$5.26	$0.94	$0.74	$0.70	$0.91	$0.82	$0.78	$0.75	$0.59	$0.81
Adjusted Weighted Average Diluted Shares Outstanding	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.76B	1.76B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.74B	1.73B	1.73B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B
Normalized Net Operating Profit after Tax (NOPAT)	1,262	1,338	1,577	1,352	1,182	1,581	1,415	1,296	1,273	1,020	1,445
Normalized NOPAT Margin	12.18%	12.19%	14.83%	13.03%	11.87%	15.43%	13.95%	12.99%	13.06%	10.11%	13.88%
Pre Tax Income Margin	17.17%	18.50%	18.24%	15.49%	14.41%	17.53%	16.47%	16.40%	16.03%	13.08%	16.89%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	13.95	15.26	14.02	11.89	10.62	11.73	10.48	10.67	10.55	9.00	13.08
NOPAT to Interest Expense	9.63	63.88	11.11	9.66	8.39	9.94	8.53	8.15	8.32	6.63	10.25
EBIT Less CapEx to Interest Expense	10.25	9.96	10.11	8.09	7.79	6.98	7.11	7.48	8.07	5.04	9.77
NOPAT Less CapEx to Interest Expense	5.94	58.59	7.19	5.85	5.56	5.19	5.15	4.96	5.84	2.67	6.93
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	28.92%	28.62%	65.30%	66.47%	64.35%	62.14%	67.63%	66.44%	58.01%	47.73%	41.63%
Augmented Payout Ratio	38.91%	38.29%	86.79%	75.29%	80.57%	83.58%	99.65%	113.89%	92.95%	102.47%	93.40%

Frequently Asked Questions About Abbott Laboratories' Financials

When does Abbott Laboratories's fiscal year end?

According to the most recent income statement we have on file, Abbott Laboratories' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Abbott Laboratories' net income changed over the last 9 years?

Abbott Laboratories' net income appears to be on an upward trend, with a most recent value of $13.40 billion in 2024, rising from $4.42 billion in 2015. The previous period was $5.72 billion in 2023. See Abbott Laboratories' forecast for analyst expectations on what’s next for the company.

What is Abbott Laboratories's operating income?

Abbott Laboratories's total operating income in 2024 was $6.83 billion, based on the following breakdown:

Total Gross Profit: $23.24 billion
Total Operating Expenses: $16.42 billion

How has Abbott Laboratories revenue changed over the last 9 years?

Over the last 9 years, Abbott Laboratories' total revenue changed from $20.41 billion in 2015 to $41.95 billion in 2024, a change of 105.6%.

How much debt does Abbott Laboratories have?

Abbott Laboratories' total liabilities were at $33.51 billion at the end of 2024, a 2.5% decrease from 2023, and a 68.2% increase since 2015.

How much cash does Abbott Laboratories have?

In the past 9 years, Abbott Laboratories' cash and equivalents has ranged from $3.84 billion in 2018 to $18.62 billion in 2016, and is currently $7.62 billion as of their latest financial filing in 2024.

How has Abbott Laboratories' book value per share changed over the last 9 years?

Over the last 9 years, Abbott Laboratories' book value per share changed from 14.18 in 2015 to 27.48 in 2024, a change of 93.8%.

Related Companies

This page (NYSE:ABT) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Financials

Frequently Asked Questions About Abbott Laboratories' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abbott Laboratories (ABT) Financials

Annual Income Statements for Abbott Laboratories

Quarterly Income Statements for Abbott Laboratories

Annual Cash Flow Statements for Abbott Laboratories

Quarterly Cash Flow Statements for Abbott Laboratories

Annual Balance Sheets for Abbott Laboratories

Quarterly Balance Sheets for Abbott Laboratories

Annual Metrics And Ratios for Abbott Laboratories

Quarterly Metrics And Ratios for Abbott Laboratories

Frequently Asked Questions About Abbott Laboratories' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools